Hikma gave a lacklustre Q3 16 trading update (no numbers) and has lowered its FY 16 revenue guidance (at cc) to $2bn from the previous $2-2.1bn. This was primarily on account of the continued sluggishness of the Generics segment. The Branded segment is also faring below expectations, besides facing higher-than-anticipated currency headwinds. The only positive is the sustained outperformance of the Injectables segment.
30 Nov 2016
Stuttering Generics weighs further on weak sentiment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Stuttering Generics weighs further on weak sentiment
Hikma Pharmaceuticals Plc (HIK:LON) | 1,798 269.6 0.8% | Mkt Cap: 3,988m
- Published:
30 Nov 2016 -
Author:
Jyoti Prakash -
Pages:
3
Hikma gave a lacklustre Q3 16 trading update (no numbers) and has lowered its FY 16 revenue guidance (at cc) to $2bn from the previous $2-2.1bn. This was primarily on account of the continued sluggishness of the Generics segment. The Branded segment is also faring below expectations, besides facing higher-than-anticipated currency headwinds. The only positive is the sustained outperformance of the Injectables segment.